Identification

Name
Atazanavir
Accession Number
DB01072  (APRD00804)
Type
Small Molecule
Groups
Approved, Investigational
Description

Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once-daily (rather than requiring multiple doses per day) and has lesser effects on the patient's lipid profile (the amounts of cholesterol and other fatty substances in the blood). Like other protease inhibitors, it is used only in combination with other HIV medications. The U.S. Food and Drug Administration (FDA) approved atazanavir on June 20, 2003. [Wikipedia]

Structure
Thumb
Synonyms
  • Atazanavirum
  • ATV
  • ATZ
  • Latazanavir
  • Zrivada
External IDs
BMS-232632 / CGP-73547
Product Ingredients
IngredientUNIICASInChI Key
Atazanavir sulfate4MT4VIE29P229975-97-7DQSGVVGOPRWTKI-QVFAWCHISA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Mylan-atazanavirCapsule150 mgOralMylan Pharmaceuticals2017-05-03Not applicableCanada
Mylan-atazanavirCapsule300 mgOralMylan Pharmaceuticals2017-05-02Not applicableCanada
Mylan-atazanavirCapsule200 mgOralMylan Pharmaceuticals2017-05-03Not applicableCanada
ReyatazCapsule, gelatin coated300 mg/1OralE.R. Squibb & Sons, L.L.C.2003-06-24Not applicableUs
ReyatazCapsule, gelatin coated150 mg/1OralRemedy Repack2013-03-262016-03-31Us
ReyatazCapsule200 mgOralBristol Myers Squibb Pharma Eeig2004-03-02Not applicableEu
ReyatazCapsule100 mgOralBristol Myers Squibb Pharma Eeig2004-03-02Not applicableEu
ReyatazCapsule, gelatin coated150 mg/1OralAvera Mc Kennan Hospital2015-04-28Not applicableUs
ReyatazCapsule150 mgOralBristol Myers Squibb2004-01-09Not applicableCanada
ReyatazPowder50 mgOralBristol Myers Squibb Pharma Eeig2004-03-02Not applicableEu
International/Other Brands
Latazanavir / Zrivada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
EvotazAtazanavir sulfate (300 mg/1) + Cobicistat (150 mg/1)TabletOralA S Medication Solutions2015-01-292017-06-20Us
EvotazAtazanavir sulfate (300 mg/1) + Cobicistat (150 mg/1)TabletOralE.R. Squibb & Sons, L.L.C.2015-01-29Not applicableUs
EvotazAtazanavir sulfate (300 mg/1) + Cobicistat (150 mg/1)TabletOralA S Medication Solutions2015-01-292017-06-20Us
EvotazAtazanavir (300 mg) + Cobicistat (150 mg)TabletOralBristol Myers Squibb2016-02-11Not applicableCanada
Categories
UNII
QZU4H47A3S
CAS number
198904-31-3
Weight
Average: 704.8555
Monoisotopic: 704.389748048
Chemical Formula
C38H52N6O7
InChI Key
AXRYRYVKAWYZBR-GASGPIRDSA-N
InChI
InChI=1S/C38H52N6O7/c1-37(2,3)31(41-35(48)50-7)33(46)40-29(22-25-14-10-9-11-15-25)30(45)24-44(43-34(47)32(38(4,5)6)42-36(49)51-8)23-26-17-19-27(20-18-26)28-16-12-13-21-39-28/h9-21,29-32,45H,22-24H2,1-8H3,(H,40,46)(H,41,48)(H,42,49)(H,43,47)/t29-,30-,31+,32+/m0/s1
IUPAC Name
methyl N-[(1S)-1-{[(2S,3S)-3-hydroxy-4-[(2S)-2-[(methoxycarbonyl)amino]-3,3-dimethyl-N'-{[4-(pyridin-2-yl)phenyl]methyl}butanehydrazido]-1-phenylbutan-2-yl]carbamoyl}-2,2-dimethylpropyl]carbamate
SMILES
COC(=O)N[[email protected]](C(=O)N[[email protected]@H](CC1=CC=CC=C1)[[email protected]@H](O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)[[email protected]@H](NC(=O)OC)C(C)(C)C)C(C)(C)C

Pharmacology

Indication

Used in combination with other antiretroviral agents for the treatment of HIV-1 infection, as well as postexposure prophylaxis of HIV infection in individuals who have had occupational or nonoccupational exposure to potentially infectious body fluids of a person known to be infected with HIV when that exposure represents a substantial risk for HIV transmission.

Structured Indications
Pharmacodynamics

Atazanavir (ATV) is an azapeptide HIV-1 protease inhibitor (PI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Atazanavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs. Atazanivir is pharmacologically related but structurally different from other protease inhibitors and other currently available antiretrovirals.

Mechanism of action

Atazanavir selectively inhibits the virus-specific processing of viral Gag and Gag-Pol polyproteins in HIV-1 infected cells by binding to the active site of HIV-1 protease, thus preventing the formation of mature virions. Atazanavir is not active against HIV-2.

TargetActionsOrganism
AHuman immunodeficiency virus type 1 protease
inhibitor
Human immunodeficiency virus 1
Absorption

Atazanavir is rapidly absorbed with a Tmax of approximately 2.5 hours. Administration of atazanavir with food enhances bioavailability and reduces pharmacokinetic variability. Oral bioavailability is 60-68%.

Volume of distribution
Not Available
Protein binding

86% bound to human serum proteins (alpha-1-acid glycoprotein and albumin). Protein binding is independent of concentration.

Metabolism

Atazanavir is extensively metabolized in humans, primarily by the liver. The major biotransformation pathways of atazanavir in humans consisted of monooxygenation and dioxygenation. Other minor biotransformation pathways for atazanavir or its metabolites consisted of glucuronidation, N-dealkylation, hydrolysis, and oxygenation with dehydrogenation. In vitro studies using human liver microsomes suggested that atazanavir is metabolized by CYP3A.

Route of elimination
Not Available
Half life

Elimination half-life in adults (healthy and HIV infected) is approximately 7 hours (following a 400 mg daily dose with a light meal). Elimination half-life in hepatically impaired is 12.1 hours (following a single 400 mg dose).

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Human Immunodeficiency Virus
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
UDP-glucuronosyltransferase 1-1UGT1A1*28(TA;TA)TA pair insertionADR Directly StudiedThe presence of this genotype in UGT1A1 may indicate an increased risk of hyperbilirubinemia from atazanavir treatment.Details
UDP-glucuronosyltransferase 1-1UGT1A1*37(TA;TA)TA pair insertionADR Directly StudiedThe presence of this genotype in UGT1A1 may indicate an increased risk of hyperbilirubinemia from atazanavir treatment.Details
UDP-glucuronosyltransferase 1-1UGT1A1*80(T;T)G > A, homozygousADR Directly StudiedThe presence of this genotype in UGT1A1 may indicate an increased risk of hyperbilirubinemia from atazanavir treatment.Details

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Atazanavir.Investigational
19-norandrostenedioneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Atazanavir.Experimental, Illicit
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Atazanavir.Investigational
5-androstenedioneThe serum concentration of 5-androstenedione can be increased when it is combined with Atazanavir.Experimental, Illicit
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Atazanavir.Approved, Investigational
AbemaciclibThe risk or severity of adverse effects can be increased when Atazanavir is combined with Abemaciclib.Approved
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Atazanavir.Approved
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Atazanavir.Approved, Investigational
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Atazanavir.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Atazanavir.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Atazanavir.Investigational, Withdrawn
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Atazanavir.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Atazanavir.Approved
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Atazanavir.Experimental, Investigational
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Atazanavir.Approved, Vet Approved
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Atazanavir.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Atazanavir.Experimental, Investigational
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Atazanavir.Approved, Illicit
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Atazanavir.Approved, Investigational
AliskirenThe metabolism of Aliskiren can be decreased when combined with Atazanavir.Approved, Investigational
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Atazanavir.Investigational
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Atazanavir.Approved
AlmasilateAlmasilate can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Atazanavir.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Atazanavir.Approved
AloglutamolAloglutamol can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AlosetronThe serum concentration of Alosetron can be increased when it is combined with Atazanavir.Approved, Withdrawn
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Atazanavir.Approved, Illicit, Investigational
AluminiumAluminium can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Atazanavir.Approved, Investigational
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Atazanavir.Approved, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Atazanavir.Experimental, Investigational
AmcinonideThe serum concentration of Amcinonide can be increased when it is combined with Atazanavir.Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Atazanavir.Illicit, Withdrawn
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Atazanavir.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Atazanavir.Approved
AmiodaroneThe serum concentration of Amiodarone can be increased when it is combined with Atazanavir.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Atazanavir.Approved
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Atazanavir.Approved
AmoxapineThe serum concentration of Amoxapine can be increased when it is combined with Atazanavir.Approved
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Atazanavir.Approved
AnagrelideAtazanavir may increase the QTc-prolonging activities of Anagrelide.Approved
AndrostenedioneThe serum concentration of Androstenedione can be increased when it is combined with Atazanavir.Experimental, Illicit
AnecortaveThe serum concentration of Anecortave can be increased when it is combined with Atazanavir.Investigational
anecortave acetateThe serum concentration of anecortave acetate can be increased when it is combined with Atazanavir.Investigational
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Atazanavir.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Atazanavir.Approved
ApremilastThe metabolism of Apremilast can be decreased when combined with Atazanavir.Approved, Investigational
AprepitantThe serum concentration of Atazanavir can be increased when it is combined with Aprepitant.Approved, Investigational
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Atazanavir.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Atazanavir.Approved, Investigational
Arsenic trioxideAtazanavir may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Atazanavir.Approved
AsenapineThe serum concentration of Atazanavir can be decreased when it is combined with Asenapine.Approved
AstemizoleThe serum concentration of Astemizole can be increased when it is combined with Atazanavir.Approved, Withdrawn
AtamestaneThe serum concentration of Atamestane can be increased when it is combined with Atazanavir.Investigational
AtomoxetineThe metabolism of Atazanavir can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Atazanavir.Approved
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Atazanavir.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Atazanavir.Approved, Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Atazanavir.Approved
AzithromycinThe metabolism of Azithromycin can be decreased when combined with Atazanavir.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Atazanavir.Investigational
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Atazanavir.Investigational
BarnidipineThe serum concentration of Barnidipine can be increased when it is combined with Atazanavir.Approved
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Atazanavir.Approved, Investigational
BedaquilineThe serum concentration of Bedaquiline can be increased when it is combined with Atazanavir.Approved
BelinostatThe serum concentration of Belinostat can be increased when it is combined with Atazanavir.Approved, Investigational
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Atazanavir.Investigational
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Atazanavir.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Atazanavir.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Atazanavir.Approved, Vet Approved
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Atazanavir.Approved, Investigational
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Atazanavir.Approved
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Atazanavir.Approved
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Atazanavir.Approved
BoceprevirThe serum concentration of Atazanavir can be decreased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe serum concentration of Bortezomib can be increased when it is combined with Atazanavir.Approved, Investigational
BosentanThe serum concentration of Atazanavir can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Atazanavir.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Atazanavir.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Atazanavir.Approved
BrinzolamideThe serum concentration of Brinzolamide can be increased when it is combined with Atazanavir.Approved
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Atazanavir.Approved, Investigational
BromazepamThe metabolism of Bromazepam can be decreased when combined with Atazanavir.Approved, Illicit
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Atazanavir.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Atazanavir.Approved
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Atazanavir.Approved
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Atazanavir.Investigational, Withdrawn
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Atazanavir.Approved, Investigational
BuprenorphineThe serum concentration of Atazanavir can be decreased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Atazanavir.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Atazanavir.Approved, Investigational
BusulfanThe metabolism of Busulfan can be decreased when combined with Atazanavir.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Atazanavir.Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Atazanavir.Approved
CabozantinibThe serum concentration of Cabozantinib can be increased when it is combined with Atazanavir.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Atazanavir.Approved
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Atazanavir.Approved, Nutraceutical
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium silicateCalcium silicate can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CanagliflozinThe metabolism of Canagliflozin can be decreased when combined with Atazanavir.Approved
CapecitabineThe metabolism of Atazanavir can be decreased when combined with Capecitabine.Approved, Investigational
CarbamazepineThe metabolism of Atazanavir can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Atazanavir.Approved
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Atazanavir.Experimental
CariprazineThe metabolism of Cariprazine can be decreased when combined with Atazanavir.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Atazanavir.Approved, Investigational
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Atazanavir.Experimental
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Atazanavir.Approved, Investigational
CeliprololThe metabolism of Celiprolol can be decreased when combined with Atazanavir.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Atazanavir.Approved, Vet Approved
CeritinibThe serum concentration of Atazanavir can be increased when it is combined with Ceritinib.Approved
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Atazanavir.Withdrawn
CevimelineThe metabolism of Cevimeline can be decreased when combined with Atazanavir.Approved
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Atazanavir.Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Atazanavir.Approved, Illicit
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Atazanavir.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Atazanavir.Investigational, Withdrawn
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Atazanavir.Approved
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Atazanavir.Approved, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Atazanavir.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Atazanavir.Approved
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Atazanavir.Approved, Nutraceutical
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Atazanavir.Approved, Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Atazanavir.Experimental
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Atazanavir.Approved
CimetidineThe serum concentration of Atazanavir can be decreased when it is combined with Cimetidine.Approved
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Atazanavir.Approved
CiprofloxacinAtazanavir may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Atazanavir.Approved, Investigational, Withdrawn
CitalopramThe metabolism of Citalopram can be decreased when combined with Atazanavir.Approved
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Atazanavir.Approved
ClemastineThe metabolism of Atazanavir can be decreased when combined with Clemastine.Approved
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Atazanavir.Approved, Vet Approved
ClobazamThe metabolism of Clobazam can be decreased when combined with Atazanavir.Approved, Illicit
ClobetasolThe serum concentration of Clobetasol can be increased when it is combined with Atazanavir.Investigational
Clobetasol propionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Atazanavir.Approved
ClobetasoneThe serum concentration of Clobetasone can be increased when it is combined with Atazanavir.Approved
ClocortoloneThe serum concentration of Clocortolone can be increased when it is combined with Atazanavir.Approved
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Atazanavir.Approved, Investigational
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Atazanavir.Approved, Investigational
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Atazanavir.Investigational
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Atazanavir.Approved, Vet Approved
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Atazanavir.Approved, Illicit
ClonidineThe metabolism of Clonidine can be decreased when combined with Atazanavir.Approved
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Atazanavir.Approved, Nutraceutical
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Atazanavir.Approved, Illicit
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Atazanavir.Approved, Illicit
ClotrimazoleThe metabolism of Atazanavir can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Clozapine can be decreased when combined with Atazanavir.Approved
CobicistatThe metabolism of Atazanavir can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Atazanavir.Approved
CocaineThe metabolism of Cocaine can be decreased when combined with Atazanavir.Approved, Illicit
CodeineThe metabolism of Codeine can be decreased when combined with Atazanavir.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Atazanavir.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Atazanavir.Approved, Investigational
Conjugated estrogensThe metabolism of Conjugated estrogens can be decreased when combined with Atazanavir.Approved
CopanlisibThe metabolism of Copanlisib can be decreased when combined with Atazanavir.Approved
Cortexolone 17α-propionateThe serum concentration of Cortexolone 17α-propionate can be increased when it is combined with Atazanavir.Investigational
CorticosteroneThe serum concentration of Corticosterone can be increased when it is combined with Atazanavir.Experimental
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Atazanavir.Approved
CrisaboroleThe metabolism of Atazanavir can be decreased when combined with Crisaborole.Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Atazanavir.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Atazanavir.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Atazanavir is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Atazanavir.Approved, Investigational, Vet Approved
CytarabineThe metabolism of Cytarabine can be decreased when combined with Atazanavir.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Atazanavir.Approved
DabrafenibThe serum concentration of Atazanavir can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Daclatasvir can be increased when it is combined with Atazanavir.Approved
DantroleneThe metabolism of Dantrolene can be decreased when combined with Atazanavir.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Atazanavir.Approved
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Atazanavir.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Atazanavir.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Atazanavir.Approved, Investigational
DarunavirThe metabolism of Darunavir can be decreased when combined with Atazanavir.Approved
DasabuvirThe serum concentration of Dasabuvir can be increased when it is combined with Atazanavir.Approved
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Atazanavir.Approved, Investigational
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Atazanavir.Approved
DeferasiroxThe serum concentration of Atazanavir can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe metabolism of Deflazacort can be decreased when combined with Atazanavir.Approved
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Atazanavir.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Atazanavir.Investigational
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Atazanavir.Approved
DesogestrelThe serum concentration of Desogestrel can be increased when it is combined with Atazanavir.Approved
DesonideThe serum concentration of Desonide can be increased when it is combined with Atazanavir.Approved, Investigational
DesoximetasoneThe serum concentration of Desoximetasone can be increased when it is combined with Atazanavir.Approved
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Atazanavir.Approved
Desoxycorticosterone PivalateThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Atazanavir.Experimental, Vet Approved
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Atazanavir.Approved
DeutetrabenazineThe metabolism of Deutetrabenazine can be decreased when combined with Atazanavir.Approved, Investigational
DexamethasoneThe metabolism of Dexamethasone can be decreased when combined with Atazanavir.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Atazanavir.Vet Approved
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Atazanavir.Approved
DexlansoprazoleDexlansoprazole can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DexrabeprazoleDexrabeprazole can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Atazanavir.Approved
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Atazanavir.Approved, Illicit, Investigational, Withdrawn
DiazepamThe metabolism of Diazepam can be decreased when combined with Atazanavir.Approved, Illicit, Vet Approved
DibenzepinThe serum concentration of Dibenzepin can be increased when it is combined with Atazanavir.Experimental
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Atazanavir.Approved, Vet Approved
DidanosineThe serum concentration of Atazanavir can be decreased when it is combined with Didanosine.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Atazanavir.Approved, Investigational
DienogestThe serum concentration of Dienogest can be increased when it is combined with Atazanavir.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Atazanavir.Approved, Investigational
DiflorasoneThe serum concentration of Diflorasone can be increased when it is combined with Atazanavir.Approved
DifluocortoloneThe serum concentration of Difluocortolone can be increased when it is combined with Atazanavir.Approved, Investigational
DifluprednateThe serum concentration of Difluprednate can be increased when it is combined with Atazanavir.Approved
DigitoxinThe metabolism of Digitoxin can be decreased when combined with Atazanavir.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Atazanavir.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Atazanavir.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Atazanavir.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Atazanavir.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Atazanavir.Experimental
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Atazanavir.Approved
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Atazanavir.Approved
DisopyramideThe metabolism of Disopyramide can be decreased when combined with Atazanavir.Approved
DisulfiramThe therapeutic efficacy of Disulfiram can be decreased when used in combination with Atazanavir.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Atazanavir.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Atazanavir.Approved
DolasetronThe metabolism of Dolasetron can be decreased when combined with Atazanavir.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Atazanavir.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Atazanavir.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Atazanavir.Approved
DosulepinThe metabolism of Atazanavir can be decreased when combined with Dosulepin.Approved
DoxepinThe serum concentration of Atazanavir can be decreased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Atazanavir.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Atazanavir.Approved, Investigational
DoxycyclineThe metabolism of Atazanavir can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Atazanavir.Approved, Illicit
DronedaroneThe serum concentration of Dronedarone can be increased when it is combined with Atazanavir.Approved
DroperidolAtazanavir may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
DrospirenoneThe serum concentration of Drospirenone can be increased when it is combined with Atazanavir.Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Atazanavir.Approved
DutasterideThe serum concentration of Dutasteride can be increased when it is combined with Atazanavir.Approved, Investigational
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Atazanavir.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Atazanavir.Approved
EfavirenzThe serum concentration of Atazanavir can be decreased when it is combined with Efavirenz.Approved, Investigational
ElbasvirThe metabolism of Elbasvir can be decreased when combined with Atazanavir.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Atazanavir.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Atazanavir.Approved
EluxadolineThe serum concentration of Eluxadoline can be increased when it is combined with Atazanavir.Approved
ElvitegravirThe serum concentration of Elvitegravir can be increased when it is combined with Atazanavir.Approved
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Atazanavir.Approved
EnalaprilThe metabolism of Enalapril can be decreased when combined with Atazanavir.Approved, Vet Approved
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Atazanavir.Approved
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Atazanavir.Approved, Investigational
EnzalutamideThe serum concentration of Atazanavir can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Atazanavir can be decreased when it is combined with Epinastine.Approved, Investigational
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Atazanavir.Approved
EquileninThe serum concentration of Equilenin can be increased when it is combined with Atazanavir.Experimental
EquilinThe serum concentration of Equilin can be increased when it is combined with Atazanavir.Approved
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Atazanavir.Approved, Nutraceutical
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Atazanavir.Approved
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Atazanavir.Approved
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Atazanavir.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Atazanavir.Approved, Investigational
ErythromycinThe metabolism of Erythromycin can be decreased when combined with Atazanavir.Approved, Vet Approved
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Atazanavir.Approved, Investigational
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Atazanavir.Investigational
EsomeprazoleEsomeprazole can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
EstazolamThe serum concentration of Estazolam can be increased when it is combined with Atazanavir.Approved, Illicit
EstradiolThe metabolism of Estradiol can be decreased when combined with Atazanavir.Approved, Investigational, Vet Approved
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Atazanavir.Approved, Investigational
EstramustineThe metabolism of Estramustine can be decreased when combined with Atazanavir.Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Atazanavir.Approved
EstroneThe metabolism of Estrone can be decreased when combined with Atazanavir.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Atazanavir.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Atazanavir.Approved
EthanolThe metabolism of Ethanol can be decreased when combined with Atazanavir.Approved
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Atazanavir.Approved
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Atazanavir.Approved
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Atazanavir.Approved, Illicit
Ethynodiol diacetateThe serum concentration of Ethynodiol diacetate can be increased when it is combined with Atazanavir.Approved
EtizolamThe serum concentration of Etizolam can be increased when it is combined with Atazanavir.Approved
EtonogestrelThe serum concentration of Etonogestrel can be increased when it is combined with Atazanavir.Approved, Investigational
EtoposideThe metabolism of Etoposide can be decreased when combined with Atazanavir.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Atazanavir.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Atazanavir.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Atazanavir.Approved
ExemestaneThe metabolism of Exemestane can be decreased when combined with Atazanavir.Approved, Investigational
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Atazanavir.Approved, Investigational
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Atazanavir.Approved
FamotidineThe serum concentration of Atazanavir can be decreased when it is combined with Famotidine.Approved
FelbamateThe metabolism of Felbamate can be decreased when combined with Atazanavir.Approved
FelodipineThe metabolism of Felodipine can be decreased when combined with Atazanavir.Approved, Investigational
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Atazanavir.Approved
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Atazanavir.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Atazanavir.Approved
FinasterideThe metabolism of Finasteride can be decreased when combined with Atazanavir.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Atazanavir.Approved, Investigational
FlecainideAtazanavir may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Atazanavir.Approved
FloxuridineThe metabolism of Atazanavir can be decreased when combined with Floxuridine.Approved
fluasteroneThe serum concentration of fluasterone can be increased when it is combined with Atazanavir.Investigational
FluconazoleThe metabolism of Atazanavir can be decreased when combined with Fluconazole.Approved
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Atazanavir.Approved
FlumethasoneThe serum concentration of Flumethasone can be increased when it is combined with Atazanavir.Approved, Vet Approved
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Atazanavir.Approved, Investigational
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Atazanavir.Approved, Illicit
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Atazanavir.Approved, Investigational, Vet Approved
FluocinonideThe serum concentration of Fluocinonide can be increased when it is combined with Atazanavir.Approved, Investigational
FluocortoloneThe serum concentration of Fluocortolone can be increased when it is combined with Atazanavir.Approved, Withdrawn
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Atazanavir.Approved
FluorouracilThe metabolism of Atazanavir can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Atazanavir.Approved, Vet Approved
FlupentixolAtazanavir may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluprednideneThe serum concentration of Fluprednidene can be increased when it is combined with Atazanavir.Approved, Withdrawn
FluprednisoloneThe serum concentration of Fluprednisolone can be increased when it is combined with Atazanavir.Approved
FlurandrenolideThe serum concentration of Flurandrenolide can be increased when it is combined with Atazanavir.Approved
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Atazanavir.Approved, Illicit
FlutamideThe metabolism of Flutamide can be decreased when combined with Atazanavir.Approved
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Atazanavir.Approved
Fluticasone propionateThe serum concentration of Fluticasone propionate can be increased when it is combined with Atazanavir.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Atazanavir.Approved
FluvoxamineThe metabolism of Atazanavir can be decreased when combined with Fluvoxamine.Approved, Investigational
FormestaneThe serum concentration of Formestane can be increased when it is combined with Atazanavir.Approved, Investigational, Withdrawn
FosamprenavirThe metabolism of Fosamprenavir can be decreased when combined with Atazanavir.Approved
FosaprepitantThe serum concentration of Atazanavir can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Atazanavir can be increased when combined with Fosphenytoin.Approved
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Atazanavir.Approved, Investigational
Fusidic AcidThe serum concentration of Atazanavir can be increased when it is combined with Fusidic Acid.Approved
Gadobenic acidAtazanavir may increase the QTc-prolonging activities of Gadobenic acid.Approved
GalantamineThe metabolism of Galantamine can be decreased when combined with Atazanavir.Approved
GarlicThe serum concentration of Atazanavir can be decreased when it is combined with Garlic.Approved
GefitinibThe metabolism of Gefitinib can be decreased when combined with Atazanavir.Approved, Investigational
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Atazanavir.Approved
GemifloxacinAtazanavir may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GestodeneThe serum concentration of Gestodene can be increased when it is combined with Atazanavir.Approved, Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Atazanavir.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Atazanavir.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Atazanavir.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Atazanavir.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Atazanavir.Approved, Investigational
GlyburideThe metabolism of Glyburide can be decreased when combined with Atazanavir.Approved
GoserelinAtazanavir may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronThe metabolism of Granisetron can be decreased when combined with Atazanavir.Approved, Investigational
GrazoprevirThe metabolism of Grazoprevir can be decreased when combined with Atazanavir.Approved
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Atazanavir.Investigational, Withdrawn
GuanfacineThe serum concentration of Guanfacine can be increased when it is combined with Atazanavir.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Atazanavir.Investigational
HalcinonideThe serum concentration of Halcinonide can be increased when it is combined with Atazanavir.Approved, Investigational, Withdrawn
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Atazanavir.Approved
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Atazanavir.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Atazanavir.Approved, Vet Approved
HE3286The serum concentration of HE3286 can be increased when it is combined with Atazanavir.Investigational
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Atazanavir.Withdrawn
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Atazanavir.Approved
HistamineThe metabolism of Histamine can be decreased when combined with Atazanavir.Approved, Investigational
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Atazanavir.Approved, Illicit
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Atazanavir.Approved, Vet Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Atazanavir.Approved, Illicit
HydrotalciteHydrotalcite can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Atazanavir.Approved
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Atazanavir.Approved
IbutilideAtazanavir may increase the QTc-prolonging activities of Ibutilide.Approved
IcotinibThe metabolism of Icotinib can be decreased when combined with Atazanavir.Approved, Investigational
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Atazanavir.Approved
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Atazanavir resulting in a loss in efficacy.Approved
IloperidoneThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Atazanavir.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Atazanavir.Approved
ImidafenacinThe serum concentration of Imidafenacin can be increased when it is combined with Atazanavir.Approved, Investigational
ImipramineThe metabolism of Imipramine can be decreased when combined with Atazanavir.Approved
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Atazanavir.Approved, Investigational
IndacaterolThe metabolism of Indacaterol can be decreased when combined with Atazanavir.Approved
IndapamideThe metabolism of Indapamide can be decreased when combined with Atazanavir.Approved
IndinavirThe risk or severity of adverse effects can be increased when Atazanavir is combined with Indinavir.Approved
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Atazanavir.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Atazanavir.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Atazanavir.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Atazanavir.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Atazanavir.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Atazanavir.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Atazanavir.Approved
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Atazanavir.Approved
IprindoleThe serum concentration of Iprindole can be increased when it is combined with Atazanavir.Experimental
IrbesartanThe metabolism of Atazanavir can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Atazanavir.Approved, Investigational
IsavuconazoniumThe serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with Atazanavir.Approved, Investigational
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Atazanavir.Approved
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Atazanavir.Approved
IsradipineThe metabolism of Isradipine can be decreased when combined with Atazanavir.Approved
IstaroximeThe serum concentration of Istaroxime can be increased when it is combined with Atazanavir.Investigational
ItraconazoleThe metabolism of Itraconazole can be decreased when combined with Atazanavir.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Atazanavir.Approved
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Atazanavir.Approved
IvermectinThe metabolism of Ivermectin can be decreased when combined with Atazanavir.Approved, Vet Approved
IxabepiloneThe serum concentration of Ixabepilone can be increased when it is combined with Atazanavir.Approved, Investigational
IxazomibThe metabolism of Ixazomib can be decreased when combined with Atazanavir.Approved
KetamineThe metabolism of Ketamine can be decreased when combined with Atazanavir.Approved, Vet Approved
KetazolamThe metabolism of Ketazolam can be decreased when combined with Atazanavir.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Atazanavir.Approved, Investigational
KetoconazoleThe metabolism of Atazanavir can be decreased when combined with Ketoconazole.Approved, Investigational
LacosamideThe serum concentration of Lacosamide can be increased when it is combined with Atazanavir.Approved
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Atazanavir.Approved, Investigational
LansoprazoleLansoprazole can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LapatinibThe serum concentration of Lapatinib can be increased when it is combined with Atazanavir.Approved, Investigational
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Atazanavir.Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Atazanavir.Approved
LeflunomideThe metabolism of Atazanavir can be decreased when combined with Leflunomide.Approved, Investigational
LenvatinibThe metabolism of Lenvatinib can be decreased when combined with Atazanavir.Approved
LercanidipineThe serum concentration of Lercanidipine can be increased when it is combined with Atazanavir.Approved, Investigational
LetrozoleThe metabolism of Letrozole can be decreased when combined with Atazanavir.Approved, Investigational
LeuprolideAtazanavir may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevobupivacaineThe serum concentration of Levobupivacaine can be increased when it is combined with Atazanavir.Approved, Investigational
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Atazanavir.Approved
LevofloxacinAtazanavir may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Atazanavir.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Atazanavir.Approved
LevonorgestrelThe serum concentration of Levonorgestrel can be increased when it is combined with Atazanavir.Approved, Investigational
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Atazanavir.Approved
LidocaineThe metabolism of Lidocaine can be decreased when combined with Atazanavir.Approved, Vet Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Atazanavir.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Atazanavir.Approved
LisurideThe metabolism of Lisuride can be decreased when combined with Atazanavir.Approved, Investigational
LobeglitazoneThe metabolism of Atazanavir can be decreased when combined with Lobeglitazone.Approved, Investigational
LofepramineThe serum concentration of Lofepramine can be increased when it is combined with Atazanavir.Experimental
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Atazanavir.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Atazanavir.Approved
LopinavirThe metabolism of Lopinavir can be decreased when combined with Atazanavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Atazanavir.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Atazanavir.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Atazanavir.Approved
LoteprednolThe serum concentration of Loteprednol can be increased when it is combined with Atazanavir.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Atazanavir.Approved, Investigational
LuliconazoleThe serum concentration of Atazanavir can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Atazanavir can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe serum concentration of Lumefantrine can be increased when it is combined with Atazanavir.Approved
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Atazanavir.Approved
LynestrenolThe serum concentration of Lynestrenol can be increased when it is combined with Atazanavir.Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Atazanavir.Illicit, Investigational, Withdrawn
MacitentanThe serum concentration of Macitentan can be increased when it is combined with Atazanavir.Approved
MagaldrateMagaldrate can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium HydroxideMagnesium Hydroxide can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ManidipineThe metabolism of Atazanavir can be decreased when combined with Manidipine.Approved, Investigational
MaravirocThe serum concentration of Maraviroc can be increased when it is combined with Atazanavir.Approved, Investigational
ME-609The serum concentration of ME-609 can be increased when it is combined with Atazanavir.Investigational
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Atazanavir.Approved, Vet Approved
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Atazanavir.Approved, Investigational
MedrysoneThe serum concentration of Medrysone can be increased when it is combined with Atazanavir.Approved
MefloquineThe metabolism of Mefloquine can be decreased when combined with Atazanavir.Approved
MelengestrolThe serum concentration of Melengestrol can be increased when it is combined with Atazanavir.Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Atazanavir.Approved, Vet Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Atazanavir.Approved
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Atazanavir.Experimental
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Atazanavir.Approved
MethadoneThe metabolism of Methadone can be decreased when combined with Atazanavir.Approved
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Atazanavir.Experimental
MethanthelineThe serum concentration of Atazanavir can be decreased when it is combined with Methantheline.Approved, Investigational
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Atazanavir.Illicit, Withdrawn
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Atazanavir.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Atazanavir.Approved, Investigational, Vet Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Atazanavir.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Atazanavir.Approved, Vet Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Atazanavir.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Atazanavir.Approved
MetiamideThe serum concentration of Atazanavir can be decreased when it is combined with Metiamide.Experimental
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Atazanavir.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Atazanavir.Experimental
MexiletineThe metabolism of Mexiletine can be decreased when combined with Atazanavir.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Atazanavir.Approved, Investigational
MibefradilThe metabolism of Mibefradil can be decreased when combined with Atazanavir.Investigational, Withdrawn
MiconazoleThe metabolism of Miconazole can be decreased when combined with Atazanavir.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Atazanavir.Approved, Illicit
MidostaurinThe metabolism of Midostaurin can be decreased when combined with Atazanavir.Approved
MifepristoneThe serum concentration of Atazanavir can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Atazanavir.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Atazanavir.Approved
MinocyclineThe serum concentration of Atazanavir can be decreased when it is combined with Minocycline.Approved, Investigational
MinoxidilThe serum concentration of Minoxidil can be increased when it is combined with Atazanavir.Approved
MirabegronThe metabolism of Mirabegron can be decreased when combined with Atazanavir.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Atazanavir.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Atazanavir.Approved, Investigational
MitotaneThe serum concentration of Atazanavir can be decreased when it is combined with Mitotane.Approved
ModafinilThe metabolism of Modafinil can be decreased when combined with Atazanavir.Approved, Investigational
MometasoneThe serum concentration of Mometasone can be increased when it is combined with Atazanavir.Approved, Vet Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Atazanavir.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Atazanavir.Approved, Investigational
MoxifloxacinAtazanavir may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Atazanavir.Approved, Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Atazanavir.Approved
NaloxoneThe metabolism of Naloxone can be decreased when combined with Atazanavir.Approved, Vet Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Atazanavir.Approved, Investigational
NCX 1022The serum concentration of NCX 1022 can be increased when it is combined with Atazanavir.Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Atazanavir.Approved, Withdrawn
NelfinavirThe metabolism of Atazanavir can be decreased when combined with Nelfinavir.Approved
NeratinibThe metabolism of Neratinib can be decreased when combined with Atazanavir.Approved, Investigational
NetupitantThe serum concentration of Atazanavir can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Nevirapine can be increased when it is combined with Atazanavir.Approved
NicardipineThe metabolism of Nicardipine can be decreased when combined with Atazanavir.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Atazanavir.Approved, Investigational
NicotineThe metabolism of Nicotine can be decreased when combined with Atazanavir.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Atazanavir.Approved
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Atazanavir.Approved, Investigational
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Atazanavir.Approved, Investigational
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Atazanavir.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Atazanavir.Approved
NisoldipineThe serum concentration of Nisoldipine can be increased when it is combined with Atazanavir.Approved
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Atazanavir.Approved
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Atazanavir.Approved, Investigational
NizatidineThe serum concentration of Atazanavir can be decreased when it is combined with Nizatidine.Approved
NorelgestrominThe serum concentration of Norelgestromin can be increased when it is combined with Atazanavir.Approved
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Atazanavir.Approved
NorgestimateThe serum concentration of Norgestimate can be increased when it is combined with Atazanavir.Approved
NorgestrelThe serum concentration of Norgestrel can be increased when it is combined with Atazanavir.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Atazanavir.Approved
OdanacatibThe metabolism of Odanacatib can be decreased when combined with Atazanavir.Investigational
OfloxacinAtazanavir may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineThe serum concentration of Atazanavir can be decreased when it is combined with Olanzapine.Approved, Investigational
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Atazanavir.Approved
Oleoyl-estroneThe serum concentration of Oleoyl-estrone can be increased when it is combined with Atazanavir.Investigational
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Atazanavir.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Atazanavir.Approved
OmeprazoleOmeprazole can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Atazanavir.Approved
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Atazanavir.Investigational
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Atazanavir.Approved
OsimertinibThe serum concentration of Atazanavir can be increased when it is combined with Osimertinib.Approved
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Atazanavir.Approved
OxazepamThe metabolism of Oxazepam can be decreased when combined with Atazanavir.Approved
OxybutyninThe serum concentration of Oxybutynin can be increased when it is combined with Atazanavir.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Atazanavir is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Atazanavir.Approved, Investigational, Vet Approved
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Atazanavir.Approved, Vet Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Atazanavir.Approved, Vet Approved
PalbociclibThe serum concentration of Atazanavir can be increased when it is combined with Palbociclib.Approved
PaliperidoneAtazanavir may increase the QTc-prolonging activities of Paliperidone.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Atazanavir.Approved, Investigational
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Atazanavir.Approved, Investigational
PantoprazolePantoprazole can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Atazanavir.Approved
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Atazanavir.Approved
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Atazanavir.Approved
ParicalcitolThe serum concentration of Paricalcitol can be increased when it is combined with Atazanavir.Approved, Investigational
ParitaprevirThe serum concentration of Paritaprevir can be increased when it is combined with Atazanavir.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Atazanavir.Approved
PentamidineThe metabolism of Pentamidine can be decreased when combined with Atazanavir.Approved
PentobarbitalThe metabolism of Atazanavir can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelThe metabolism of Perampanel can be decreased when combined with Atazanavir.Approved
PerflutrenAtazanavir may increase the QTc-prolonging activities of Perflutren.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Atazanavir.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Atazanavir.Approved, Investigational
PermethrinThe metabolism of Permethrin can be decreased when combined with Atazanavir.Approved, Investigational
PerospironeThe metabolism of Perospirone can be decreased when combined with Atazanavir.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Atazanavir.Approved
PethidineThe risk or severity of adverse effects can be increased when Atazanavir is combined with Pethidine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Atazanavir.Withdrawn
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Atazanavir.Approved, Investigational, Withdrawn
PhenobarbitalThe metabolism of Atazanavir can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Atazanavir.Approved
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Atazanavir.Approved, Investigational
PhenytoinThe metabolism of Atazanavir can be increased when combined with Phenytoin.Approved, Vet Approved
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Atazanavir.Approved
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Atazanavir.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Atazanavir.Approved
PinacidilThe metabolism of Pinacidil can be decreased when combined with Atazanavir.Withdrawn
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Atazanavir.Approved, Investigational
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Atazanavir.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Atazanavir.Approved
PodofiloxThe metabolism of Podofilox can be decreased when combined with Atazanavir.Approved
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Atazanavir.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Atazanavir.Approved
PosaconazoleThe serum concentration of Atazanavir can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Atazanavir.Approved, Investigational
PranlukastThe serum concentration of Pranlukast can be increased when it is combined with Atazanavir.Approved, Investigational
PrasteroneThe metabolism of Prasterone can be decreased when combined with Atazanavir.Approved, Nutraceutical
Prasterone sulfateThe serum concentration of Prasterone sulfate can be increased when it is combined with Atazanavir.Investigational
PrasugrelThe serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Atazanavir resulting in a loss in efficacy.Approved
PravastatinThe metabolism of Pravastatin can be decreased when combined with Atazanavir.Approved
PrazepamThe metabolism of Prazepam can be decreased when combined with Atazanavir.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Atazanavir.Approved, Vet Approved
PrednicarbateThe serum concentration of Prednicarbate can be increased when it is combined with Atazanavir.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Atazanavir.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Atazanavir.Approved, Vet Approved
PregnenoloneThe serum concentration of Pregnenolone can be increased when it is combined with Atazanavir.Experimental, Investigational
PrimaquineThe metabolism of Primaquine can be decreased when combined with Atazanavir.Approved
PrimidoneThe metabolism of Atazanavir can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideAtazanavir may increase the QTc-prolonging activities of Procainamide.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Atazanavir.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Atazanavir.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Atazanavir.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Atazanavir.Approved, Vet Approved
PromethazineThe serum concentration of Atazanavir can be decreased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Atazanavir.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Atazanavir.Approved, Investigational, Vet Approved
Propoxyphene napsylateThe metabolism of Propoxyphene napsylate can be decreased when combined with Atazanavir.Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Atazanavir.Approved, Investigational
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Atazanavir.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Atazanavir.Approved
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Atazanavir.Approved
PyrimethamineThe metabolism of Atazanavir can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Atazanavir.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Atazanavir.Approved
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Atazanavir.Approved, Investigational
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Atazanavir.Approved
QuinineThe metabolism of Quinine can be decreased when combined with Atazanavir.Approved
RabeprazoleRabeprazole can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Atazanavir.Approved, Investigational
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Atazanavir.Approved, Investigational
RanitidineThe serum concentration of Atazanavir can be decreased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Atazanavir.Approved, Investigational
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Atazanavir.Approved, Investigational
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Atazanavir.Approved
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Atazanavir.Approved, Investigational
RetapamulinThe serum concentration of Retapamulin can be increased when it is combined with Atazanavir.Approved
RibociclibThe serum concentration of Ribociclib can be increased when it is combined with Atazanavir.Approved
RifabutinThe serum concentration of the active metabolites of Rifabutin can be increased when Rifabutin is used in combination with Atazanavir.Approved
RifampicinThe serum concentration of Atazanavir can be decreased when it is combined with Rifampicin.Approved
RifapentineThe metabolism of Atazanavir can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Atazanavir.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Atazanavir.Approved
RimexoloneThe serum concentration of Rimexolone can be increased when it is combined with Atazanavir.Approved
RimonabantThe metabolism of Rimonabant can be decreased when combined with Atazanavir.Approved, Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Atazanavir.Approved
RisperidoneThe metabolism of Risperidone can be decreased when combined with Atazanavir.Approved, Investigational
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Atazanavir.Approved, Investigational
RivaroxabanThe metabolism of Rivaroxaban can be decreased when combined with Atazanavir.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Atazanavir.Investigational, Withdrawn
RolapitantThe metabolism of Rolapitant can be decreased when combined with Atazanavir.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Atazanavir.Approved, Investigational
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Atazanavir.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Atazanavir.Approved
RosiglitazoneThe serum concentration of Rosiglitazone can be increased when it is combined with Atazanavir.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Atazanavir.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Atazanavir.Approved
Roxatidine acetateThe serum concentration of Atazanavir can be decreased when it is combined with Roxatidine acetate.Approved, Investigational
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Atazanavir.Approved, Investigational, Withdrawn
RucaparibThe metabolism of Rucaparib can be decreased when combined with Atazanavir.Approved, Investigational
RupatadineThe metabolism of Rupatadine can be decreased when combined with Atazanavir.Approved
RuxolitinibThe serum concentration of Ruxolitinib can be increased when it is combined with Atazanavir.Approved
SafinamideThe metabolism of Safinamide can be decreased when combined with Atazanavir.Approved
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Atazanavir.Approved
SaquinavirThe metabolism of Saquinavir can be decreased when combined with Atazanavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Atazanavir.Approved
SecobarbitalThe metabolism of Atazanavir can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Atazanavir.Approved, Investigational, Vet Approved
SelexipagThe metabolism of Selexipag can be decreased when combined with Atazanavir.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Atazanavir.Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Atazanavir.Approved, Investigational, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Atazanavir.Approved
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Atazanavir.Approved, Vet Approved
SibutramineThe metabolism of Sibutramine can be decreased when combined with Atazanavir.Approved, Illicit, Investigational, Withdrawn
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Atazanavir.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Atazanavir.Approved
SiltuximabThe serum concentration of Atazanavir can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Atazanavir can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Atazanavir.Approved
SirolimusThe metabolism of Sirolimus can be decreased when combined with Atazanavir.Approved, Investigational
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Atazanavir.Approved, Investigational
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Atazanavir.Approved
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Atazanavir.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Atazanavir.Approved, Investigational
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Atazanavir.Investigational
SotalolAtazanavir may increase the QTc-prolonging activities of Sotalol.Approved
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Atazanavir.Approved
St. John's WortThe serum concentration of Atazanavir can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Atazanavir can be increased when it is combined with Stiripentol.Approved
SufentanilThe metabolism of Sufentanil can be decreased when combined with Atazanavir.Approved, Investigational
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Atazanavir.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Atazanavir.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Atazanavir.Approved
SulfisoxazoleThe metabolism of Atazanavir can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Atazanavir.Approved, Investigational
SunitinibThe metabolism of Sunitinib can be decreased when combined with Atazanavir.Approved, Investigational
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Atazanavir.Approved
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Atazanavir.Approved
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Atazanavir.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Atazanavir.Approved, Investigational
TadalafilThe serum concentration of Tadalafil can be increased when it is combined with Atazanavir.Approved, Investigational
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Atazanavir.Approved
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Atazanavir.Approved, Investigational
TasimelteonThe serum concentration of Tasimelteon can be increased when it is combined with Atazanavir.Approved
TasosartanThe metabolism of Tasosartan can be decreased when combined with Atazanavir.Approved
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Atazanavir.Experimental
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Atazanavir.Approved, Withdrawn
TelavancinAtazanavir may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe metabolism of Atazanavir can be decreased when combined with Telithromycin.Approved
TemazepamThe metabolism of Temazepam can be decreased when combined with Atazanavir.Approved
TemsirolimusThe risk or severity of adverse effects can be increased when Atazanavir is combined with Temsirolimus.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Atazanavir.Approved
Tenofovir disoproxilThe serum concentration of Atazanavir can be decreased when it is combined with Tenofovir disoproxil.Approved, Investigational
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Atazanavir.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Atazanavir.Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Atazanavir.Experimental
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Atazanavir.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Atazanavir.Approved, Investigational
TetrabenazineAtazanavir may increase the QTc-prolonging activities of Tetrabenazine.Approved
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Atazanavir.Approved, Vet Approved
TheophyllineThe metabolism of Theophylline can be decreased when combined with Atazanavir.Approved
ThioridazineAtazanavir may increase the QTc-prolonging activities of Thioridazine.Approved, Withdrawn
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Atazanavir.Approved
TiagabineThe metabolism of Tiagabine can be decreased when combined with Atazanavir.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Atazanavir.Approved, Investigational
TicagrelorThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Atazanavir resulting in a loss in efficacy.Approved
TiclopidineThe metabolism of Ticlopidine can be decreased when combined with Atazanavir.Approved
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Atazanavir.Approved, Investigational
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Atazanavir.Approved
TipranavirThe serum concentration of Atazanavir can be decreased when it is combined with Tipranavir.Approved, Investigational
TixocortolThe serum concentration of Tixocortol can be increased when it is combined with Atazanavir.Approved
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Atazanavir.Approved
TocilizumabThe serum concentration of Atazanavir can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe serum concentration of Tofacitinib can be increased when it is combined with Atazanavir.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Atazanavir.Approved
TolbutamideThe metabolism of Atazanavir can be decreased when combined with Tolbutamide.Approved
TolterodineThe serum concentration of Tolterodine can be increased when it is combined with Atazanavir.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Atazanavir.Approved
TopiroxostatThe metabolism of Atazanavir can be decreased when combined with Topiroxostat.Approved, Investigational
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Atazanavir.Approved, Investigational
ToremifeneThe risk or severity of adverse effects can be increased when Atazanavir is combined with Toremifene.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Atazanavir.Approved, Investigational
TramadolThe serum concentration of Tramadol can be increased when it is combined with Atazanavir.Approved, Investigational
Trastuzumab emtansineThe serum concentration of the active metabolites of Trastuzumab emtansine can be increased when Trastuzumab emtansine is used in combination with Atazanavir.Approved
TrazodoneThe serum concentration of Trazodone can be increased when it is combined with Atazanavir.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Atazanavir.Approved, Investigational, Nutraceutical
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Atazanavir.Approved, Vet Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Atazanavir.Approved
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Atazanavir.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Atazanavir.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Atazanavir.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Atazanavir.Investigational, Withdrawn
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Atazanavir.Approved
TromethamineTromethamine can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Atazanavir.Approved, Investigational, Nutraceutical
UdenafilThe metabolism of Udenafil can be decreased when combined with Atazanavir.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Atazanavir.Approved
UlobetasolThe serum concentration of Ulobetasol can be increased when it is combined with Atazanavir.Approved
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Atazanavir.Approved, Investigational
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Atazanavir.Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Atazanavir.Approved, Investigational
ValsartanThe metabolism of Atazanavir can be decreased when combined with Valsartan.Approved, Investigational
VandetanibThe metabolism of Vandetanib can be decreased when combined with Atazanavir.Approved
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Atazanavir.Investigational
VardenafilThe serum concentration of Vardenafil can be increased when it is combined with Atazanavir.Approved
VelpatasvirThe metabolism of Velpatasvir can be decreased when combined with Atazanavir.Approved
VenetoclaxThe metabolism of Venetoclax can be decreased when combined with Atazanavir.Approved
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Atazanavir.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Atazanavir.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Atazanavir.Investigational
VilanterolThe metabolism of Vilanterol can be decreased when combined with Atazanavir.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Atazanavir.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Atazanavir.Approved, Investigational
VinblastineThe metabolism of Vinblastine can be decreased when combined with Atazanavir.Approved
VincristineThe metabolism of Vincristine can be decreased when combined with Atazanavir.Approved, Investigational
VincristineThe serum concentration of Vincristine can be increased when it is combined with Atazanavir.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Atazanavir.Approved, Investigational
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Atazanavir.Approved, Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Atazanavir.Approved
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Atazanavir.Approved, Investigational
VorapaxarThe serum concentration of Vorapaxar can be increased when it is combined with Atazanavir.Approved
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Atazanavir.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Atazanavir.Approved
VoxilaprevirThe metabolism of Voxilaprevir can be decreased when combined with Atazanavir.Approved
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Atazanavir.Approved
YohimbineThe metabolism of Yohimbine can be decreased when combined with Atazanavir.Approved, Vet Approved
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Atazanavir.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Atazanavir.Approved, Investigational
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Atazanavir.Approved, Illicit, Investigational
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Atazanavir.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Atazanavir.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Ziprasidone can be decreased when combined with Atazanavir.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Atazanavir.Approved
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Atazanavir.Withdrawn
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Atazanavir.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Atazanavir.Approved
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Atazanavir.Approved, Investigational
Food Interactions
  • Administration with food reduces pharmacokinetic variability.
  • Food increases product absorption.

References

Synthesis Reference
US5849911
General References
  1. Croom KF, Dhillon S, Keam SJ: Atazanavir: a review of its use in the management of HIV-1 infection. Drugs. 2009 May 29;69(8):1107-40. doi: 10.2165/00003495-200969080-00009. [PubMed:19496633]
  2. von Hentig N: Atazanavir/ritonavir: a review of its use in HIV therapy. Drugs Today (Barc). 2008 Feb;44(2):103-32. doi: 10.1358/dot.2008.44.2.1137107. [PubMed:18389089]
  3. Swainston Harrison T, Scott LJ: Atazanavir: a review of its use in the management of HIV infection. Drugs. 2005;65(16):2309-36. [PubMed:16266202]
  4. Le Tiec C, Barrail A, Goujard C, Taburet AM: Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin Pharmacokinet. 2005;44(10):1035-50. [PubMed:16176117]
  5. Lopez-Cortes LF: [Pharmacology, pharmacokinetic features and interactions of atazanavir]. Enferm Infecc Microbiol Clin. 2008 Dec;26 Suppl 17:2-8. doi: 10.1016/S0213-005X(08)76613-8. [PubMed:20116610]
  6. Busti AJ, Hall RG, Margolis DM: Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2004 Dec;24(12):1732-47. [PubMed:15585441]
External Links
Human Metabolome Database
HMDB15205
KEGG Drug
D01276
PubChem Compound
148192
PubChem Substance
46508504
ChemSpider
130642
BindingDB
13934
ChEBI
37924
ChEMBL
CHEMBL1163
Therapeutic Targets Database
DNC000332
PharmGKB
PA10251
HET
DR7
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Atazanavir
ATC Codes
J05AE08 — AtazanavirJ05AR15 — Atazanavir and cobicistat
AHFS Codes
  • 08:18.08.08 — HIV Protease Inhibitors
PDB Entries
2aqu / 2fxd / 2fxe / 2o4k / 3ekw / 3eky / 3el1 / 3el9 / 3em4 / 3oxx
FDA label
Download (412 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingOtherHIV (Adult) / HIV in Adults1
1CompletedNot AvailableChronic Hepatitis C Infection / Human Immunodeficiency Virus (HIV)1
1CompletedNot AvailableDiabetes, Diabetes Mellitus Type 11
1CompletedNot AvailableDrug Abuse / Human Immunodeficiency Virus (HIV) Infections1
1CompletedNot AvailableHealthy Volunteers2
1CompletedNot AvailableHuman Immunodeficiency Virus (HIV)1
1CompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections6
1CompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections / Human Immunodeficiency Virus Type 1 (HIV-1)1
1CompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections / Protease Inhibitors2
1CompletedNot AvailableHuman Immunodeficiency Virus Type 1 (HIV-1)1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedSupportive CareHuman Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentAntivirals/HIV1
1CompletedTreatmentHealthy Volunteers3
1CompletedTreatmentHepatitis C, Chronic / Human Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV)1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections4
1RecruitingHealth Services ResearchHuman Immunodeficiency Virus (HIV)1
1Unknown StatusBasic ScienceAtazanavir1
1, 2CompletedTreatmentChronic Hepatitis C Infection / Human Immunodeficiency Virus (HIV)1
1, 2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections3
2Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV)1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections6
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Human Immunodeficiency Virus Type 1 (HIV-1)1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Infection, Human Immunodeficiency Virus I1
2CompletedTreatmentInfection, Human Immunodeficiency Virus I2
2CompletedTreatmentType 2 Diabetes Mellitus Related Endothelial Dysfunction1
2TerminatedTreatmentHIV-infection/Aids / Human Immunodeficiency Virus (HIV) Infections1
2TerminatedTreatmentHuman Immunodeficiency Virus (HIV)1
2TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2TerminatedTreatmentInfection, Human Immunodeficiency Virus I1
2, 3CompletedBasic ScienceHuman Immunodeficiency Virus (HIV)1
2, 3CompletedTreatmentChronic Periodontitis2
2, 3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2, 3RecruitingTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) Infections1
3Active Not RecruitingTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) Infections1
3Active Not RecruitingTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) / Human Immunodeficiency Virus (HIV) Infections1
3Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV)1
3Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections2
3Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV) / Human Immunodeficiency Virus (HIV) Infections1
3Active Not RecruitingTreatmentInfection, Human Immunodeficiency Virus I2
3CompletedNot AvailableHuman Immunodeficiency Virus (HIV)1
3CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections1
3CompletedTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) Infections1
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections13
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Hyperlipidemias2
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) / Human Immunodeficiency Virus (HIV) Infections2
3CompletedTreatmentInfection, Human Immunodeficiency Virus I1
3TerminatedTreatmentHuman Immunodeficiency Virus (HIV)1
3TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
3WithdrawnTreatmentHuman Immunodeficiency Virus (HIV)2
4Active Not RecruitingTreatmentChronic Infection With HIV1
4Active Not RecruitingTreatmentHIV, Pediatric / Human Immunodeficiency Virus (HIV) Infections1
4Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV)1
4CompletedNot AvailableHealthy Volunteers1
4CompletedNot AvailableHuman Immunodeficiency Virus (HIV)1
4CompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections1
4CompletedNot AvailableHuman Immunodeficiency Virus (HIV) / Proteinuria1
4CompletedOtherHuman Immunodeficiency Virus (HIV)1
4CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections2
4CompletedTreatmentAlveolar Socket Preservations1
4CompletedTreatmentDyslipidemias / Human Immunodeficiency Virus (HIV) Infections1
4CompletedTreatmentHIV, Combination Therapy1
4CompletedTreatmentHIV, Pediatric1
4CompletedTreatmentHIV-Associated Lipodystrophy Syndrome1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV)3
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections15
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Infection, Human Immunodeficiency Virus I1
4CompletedTreatmentHuman Immunodeficiency Virus Type 1 (HIV-1)1
4CompletedTreatmentInfection, Human Immunodeficiency Virus I1
4RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
4RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections / Osteopenia1
4RecruitingTreatmentSocket Preservation1
4TerminatedPreventionHuman Immunodeficiency Virus (HIV)1
4TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections2
4TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Mitochondrial Dysfunction1
4Unknown StatusTreatmentChronic Hepatitis C Infection / Human Immunodeficiency Virus (HIV) Infections1
4Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections1
4Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections / Lipodystrophies1
4Unknown StatusTreatmentImmunosuppression-related Infectious Disease / Infection, Human Immunodeficiency Virus I1
4WithdrawnTreatmentChronic Hepatitis C Infection / Human Immunodeficiency Virus (HIV)1
Not AvailableCompletedNot AvailableHuman Immunodeficiency Virus (HIV)1
Not AvailableCompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections3
Not AvailableCompletedNot AvailableInfection, Human Immunodeficiency Virus I1
Not AvailableCompletedOtherEndothelial Dysfunction1
Not AvailableCompletedTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) / Human Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedTreatmentEndotoxaemia / Inflammatory Reaction / Multi Organ Dysfunction Syndrome / Sepsis1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections2
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Lipodystrophies / Wasting Disease1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis1
Not AvailableNo Longer AvailableNot AvailableHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableRecruitingNot AvailableMinor Patient Treated by One or More Antiretroviral and for Which a Blood Test Has Been Performed1
Not AvailableUnknown StatusTreatmentHuman Immunodeficiency Virus (HIV)1
Not AvailableWithdrawnNot AvailableHIV Infected1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
TabletOral
CapsuleOral100 mg
CapsuleOral150 mg
CapsuleOral200 mg
CapsuleOral300 mg
Capsule, gelatin coatedOral150 mg/1
Capsule, gelatin coatedOral200 mg/1
Capsule, gelatin coatedOral300 mg/1
PowderOral50 mg/1
PowderOral50 mg
Prices
Unit descriptionCostUnit
Reyataz 300 mg capsule36.63USD capsule
Reyataz 150 mg capsule18.49USD capsule
Reyataz 200 mg capsule18.49USD capsule
Reyataz 100 mg capsule18.12USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2250840No2006-07-042017-04-14Canada
CA2317736No2004-11-022018-12-22Canada
US5849911Yes1997-12-202017-12-20Us
US6087383Yes1999-06-212019-06-21Us
US8148374No2009-09-032029-09-03Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilityFree base slightly soluble (4-5 mg/mL)Not Available
logP4.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00327 mg/mLALOGPS
logP4.08ALOGPS
logP4.54ChemAxon
logS-5.3ALOGPS
pKa (Strongest Acidic)11.92ChemAxon
pKa (Strongest Basic)4.42ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area171.22 Å2ChemAxon
Rotatable Bond Count18ChemAxon
Refractivity191.8 m3·mol-1ChemAxon
Polarizability76.83 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.7997
Blood Brain Barrier-0.9409
Caco-2 permeable-0.7017
P-glycoprotein substrateSubstrate0.832
P-glycoprotein inhibitor IInhibitor0.81
P-glycoprotein inhibitor IINon-inhibitor0.844
Renal organic cation transporterNon-inhibitor0.924
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6463
CYP450 1A2 substrateNon-inhibitor0.7553
CYP450 2C9 inhibitorNon-inhibitor0.7041
CYP450 2D6 inhibitorNon-inhibitor0.848
CYP450 2C19 inhibitorNon-inhibitor0.5948
CYP450 3A4 inhibitorNon-inhibitor0.8425
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7718
Ames testNon AMES toxic0.6714
CarcinogenicityNon-carcinogens0.7261
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.7082 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9766
hERG inhibition (predictor II)Inhibitor0.6538
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as valine and derivatives. These are compounds containing valine or a derivative thereof resulting from reaction of valine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Valine and derivatives
Alternative Parents
Alpha amino acid amides / Phenylpyridines / Phenylbutylamines / Amphetamines and derivatives / N-acyl amines / Heteroaromatic compounds / Methylcarbamates / Secondary carboxylic acid amides / Secondary alcohols / Carboxylic acid hydrazides
show 7 more
Substituents
Valine or derivatives / Alpha-amino acid amide / 2-phenylpyridine / Phenylbutylamine / Amphetamine or derivatives / Monocyclic benzene moiety / Fatty amide / N-acyl-amine / Fatty acyl / Benzenoid
show 21 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
carbohydrazide (CHEBI:37924)

Targets

Kind
Protein
Organism
Human immunodeficiency virus 1
Pharmacological action
Yes
Actions
Inhibitor
General Function
Aspartic-type endopeptidase activity
Specific Function
Not Available
Gene Name
pol
Uniprot ID
Q72874
Uniprot Name
Pol polyprotein
Molecular Weight
10778.7 Da
References
  1. Dierynck I, De Wit M, Gustin E, Keuleers I, Vandersmissen J, Hallenberger S, Hertogs K: Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier. J Virol. 2007 Dec;81(24):13845-51. Epub 2007 Oct 10. [PubMed:17928344]
  2. Dandache S, Sevigny G, Yelle J, Stranix BR, Parkin N, Schapiro JM, Wainberg MA, Wu JJ: In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2007 Nov;51(11):4036-43. Epub 2007 Jul 16. [PubMed:17638694]
  3. Wood R: Atazanavir: its role in HIV treatment. Expert Rev Anti Infect Ther. 2008 Dec;6(6):785-96. doi: 10.1586/14787210.6.6.785. [PubMed:19053892]
  4. Le Tiec C, Barrail A, Goujard C, Taburet AM: Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin Pharmacokinet. 2005;44(10):1035-50. [PubMed:16176117]
  5. Pyrko P, Kardosh A, Wang W, Xiong W, Schonthal AH, Chen TC: HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress. Cancer Res. 2007 Nov 15;67(22):10920-8. [PubMed:18006837]
  6. Menendez-Arias L, Tozser J: HIV-1 protease inhibitors: effects on HIV-2 replication and resistance. Trends Pharmacol Sci. 2008 Jan;29(1):42-9. Epub 2007 Dec 4. [PubMed:18054799]
  7. Lopez-Cortes LF: [Pharmacology, pharmacokinetic features and interactions of atazanavir]. Enferm Infecc Microbiol Clin. 2008 Dec;26 Suppl 17:2-8. doi: 10.1016/S0213-005X(08)76613-8. [PubMed:20116610]
  8. Busti AJ, Hall RG, Margolis DM: Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2004 Dec;24(12):1732-47. [PubMed:15585441]
  9. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Le Tiec C, Barrail A, Goujard C, Taburet AM: Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin Pharmacokinet. 2005;44(10):1035-50. [PubMed:16176117]
  2. Busti AJ, Hall RG, Margolis DM: Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2004 Dec;24(12):1732-47. [PubMed:15585441]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Busti AJ, Hall RG, Margolis DM: Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2004 Dec;24(12):1732-47. [PubMed:15585441]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Bocedi A, Notaril S, Narciso P, Bolli A, Fasano M, Ascenzi P: Binding of anti-HIV drugs to human serum albumin. IUBMB Life. 2004 Oct;56(10):609-14. [PubMed:15814459]
  2. Bocedi A, Notari S, Menegatti E, Fanali G, Fasano M, Ascenzi P: Allosteric modulation of anti-HIV drug and ferric heme binding to human serum albumin. FEBS J. 2005 Dec;272(24):6287-96. [PubMed:16336266]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Perloff ES, Duan SX, Skolnik PR, Greenblatt DJ, von Moltke LL: Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos. 2005 Jun;33(6):764-70. Epub 2005 Mar 11. [PubMed:15764714]
  2. Lucia MB, Golotta C, Rutella S, Rastrelli E, Savarino A, Cauda R: Atazanavir inhibits P-glycoprotein and multidrug resistance-associated protein efflux activity. J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):635-7. [PubMed:16044020]
  3. Chinn LW, Gow JM, Tse MM, Becker SL, Kroetz DL: Interindividual variability in the effect of atazanavir and saquinavir on the expression of lymphocyte P-glycoprotein. J Antimicrob Chemother. 2007 Jul;60(1):61-7. Epub 2007 May 17. [PubMed:17510066]
  4. Wood R: Atazanavir: its role in HIV treatment. Expert Rev Anti Infect Ther. 2008 Dec;6(6):785-96. doi: 10.1586/14787210.6.6.785. [PubMed:19053892]
  5. Janneh O, Anwar T, Jungbauer C, Kopp S, Khoo SH, Back DJ, Chiba P: P-glycoprotein, multidrug resistance-associated proteins and human organic anion transporting polypeptide influence the intracellular accumulation of atazanavir. Antivir Ther. 2009;14(7):965-74. doi: 10.3851/IMP1399. [PubMed:19918100]
  6. Storch CH, Theile D, Lindenmaier H, Haefeli WE, Weiss J: Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol. 2007 May 15;73(10):1573-81. Epub 2007 Jan 24. [PubMed:17328866]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Transporter activity
Specific Function
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotre...
Gene Name
ABCC1
Uniprot ID
P33527
Uniprot Name
Multidrug resistance-associated protein 1
Molecular Weight
171589.5 Da
References
  1. Janneh O, Anwar T, Jungbauer C, Kopp S, Khoo SH, Back DJ, Chiba P: P-glycoprotein, multidrug resistance-associated proteins and human organic anion transporting polypeptide influence the intracellular accumulation of atazanavir. Antivir Ther. 2009;14(7):965-74. doi: 10.3851/IMP1399. [PubMed:19918100]
  2. Lucia MB, Golotta C, Rutella S, Rastrelli E, Savarino A, Cauda R: Atazanavir inhibits P-glycoprotein and multidrug resistance-associated protein efflux activity. J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):635-7. [PubMed:16044020]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2017 17:18